Business · 20/12/2004
NIH to Grant Exclusive License for Cocaine Therapeutics
The National Institutes of Health is considering granting an exclusive license to Phase2 Discovery for its cocaine therapeutics technology, which may be limited to treating Attention Deficit Hyperactivity Disorder (ADHD).